{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:28:26Z","timestamp":1790994506216,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.maturitas.2018.11.016","type":"journal-article","created":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T11:14:11Z","timestamp":1543058051000},"page":"86-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part I: Evaluation of efficacy"],"prefix":"10.1016","volume":"121","author":[{"given":"Violante","family":"Di Donato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele Carlo","family":"schiavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"iacobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavia","family":"D\u2019oria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6450-5815","authenticated-orcid":false,"given":"Evangelos","family":"Kontopantelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2971-0079","authenticated-orcid":false,"given":"Tommaso","family":"Simoncini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7195-9583","authenticated-orcid":false,"given":"Ludovico","family":"Muzii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Benedetti Panici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2018.11.016_bib0005","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40265-013-0046-y","article-title":"Ospemifene: first global approval","volume":"73","author":"Elkinson","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.maturitas.2018.11.016_bib0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4065\/mcp.2009.0413","article-title":"Vulvovaginal atrophy","volume":"85","author":"Mac Bride","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.maturitas.2018.11.016_bib0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.maturitas.2013.05.003","article-title":"The CLOSER survey: impact of postmenopausal vaginal discomfort on relationships between women and their partners in Northern and Southern Europe","volume":"75","author":"Nappi","year":"2013","journal-title":"Maturitas"},{"issue":"July-August (4 Pt 1)","key":"10.1016\/j.maturitas.2018.11.016_bib0020","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/gme.0b013e31815a5168","article-title":"Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women","volume":"15","author":"Levine","year":"2008","journal-title":"Menopause"},{"issue":"February (2)","key":"10.1016\/j.maturitas.2018.11.016_bib0025","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/jsm.12377","article-title":"The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis","volume":"11","author":"Cui","year":"2014","journal-title":"Sex. Med."},{"issue":"1","key":"10.1016\/j.maturitas.2018.11.016_bib0030","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/13697137.2015.1113517","article-title":"Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy","volume":"19","author":"Bruyniks","year":"2015","journal-title":"Climateric"},{"key":"10.1016\/j.maturitas.2018.11.016_bib0035","series-title":"Cochrane Handbook for Systematic Reviews of Interventions, v.5.1","year":"2018"},{"issue":"September-October(5)","key":"10.1016\/j.maturitas.2018.11.016_bib0040","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.GME.0000063609.62485.27","article-title":"Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial","volume":"10","author":"Rutanen","year":"2003","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2018.11.016_bib0045","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene effectively treats vulvo- vaginal atrophy in postmenopausal women: results from a pivotal phase 3 study","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause"},{"issue":"4","key":"10.1016\/j.maturitas.2018.11.016_bib0050","article-title":"One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus","volume":"20","author":"James","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2018.11.016_bib0055","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/13697137.2013.834493","article-title":"Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy","volume":"17","author":"Goldstein","year":"2014","journal-title":"Climateric"},{"issue":"6","key":"10.1016\/j.maturitas.2018.11.016_bib0060","article-title":"Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy","volume":"20","author":"David","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2018.11.016_bib0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.maturitas.2014.02.015","article-title":"Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment ovaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial","volume":"78","author":"Portman","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2018.11.016_bib0070","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0960-0760(01)00066-8","article-title":"In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer","volume":"77","author":"Taras","year":"2001","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.maturitas.2018.11.016_bib0075","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/13697137.2014.954996","article-title":"Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial","volume":"18","author":"Constantine","year":"2015","journal-title":"Climacteric"},{"issue":"July(7)","key":"10.1016\/j.maturitas.2018.11.016_bib0080","article-title":"A re-analysis of the Cochrane Library data: the dangers of unobserved heterogeneity in meta-analyses","volume":"8","author":"Kontopantelis","year":"2013","journal-title":"PLoS One"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512218307424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512218307424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:14:32Z","timestamp":1759914872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512218307424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":16,"alternative-id":["S0378512218307424"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2018.11.016","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part I: Evaluation of efficacy","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2018.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}